Harmonization of guidelines for the prevention and treatment of cardiovascular disease: The C-CHANGE Initiative

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 15, 2011, Pages

  Tobe, Sheldon W ^a   Stone, James A ^b   Brouwers, Melissa ^c   Bhattacharyya, Onil ^d   Walker, Kimberly M ^e   Dawes, Martin ^f   Genest, Jacques ^g   Grover, Steven ^h   Gubitz, Gordon ⁱ   Lau, David ^j   Pipe, Andrew ^k   Selby, Peter ^l   Tremblay, Mark S ^m   Warburton, Darren E R ^f   Ward, Richard ^j   Woo, Vincent ⁿ   Leiter, Lawrence A ^o   Liu, Peter P ^p  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁿ UNIVERSITY OF MANITOBA   (Canada)

^o ST MICHAEL'S HOSPITAL   (Canada)

^p UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONSENSUS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DRUG INDICATION; DRUG USE; DYSLIPIDEMIA; FUNDING; HEALTH BEHAVIOR; HEART DISEASE; HEART REHABILITATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; OBESITY; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SCREENING; SECONDARY PREVENTION; SMOKING CESSATION; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 80054715975     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101508     Document Type: Article

References (48)

1. Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010;303:1841-7.
2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-201.
3. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25: 567-79.
4. Quinn RR, Hemmelgarn BR, Padwal RS, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2010; 26: 241-8.
5. Stone JA, Austford L, Parker JH, et al. AGREEing on Canadian cardiovascular clinical practice guidelines. Can J Cardiol 2008;24:753-7.
6. Grol R. Successes and failures in the implementation of evidencebased guidelines for clinical practice. Med Care 2001; 39: II46-54. (Pubitemid 33752650)
7. Leiter LA, Fitchett DH, Gilbert RE, et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol 2011;27:e1-33.
8. Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2010; 26:249-58.
9. Lau DC, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007;176:S1-13.
10. Stone JA, Arthur HM, Suskin NG, editors. Canadian Association of Cardiac Rehabilitation national guidelines for cardiac rehabilitation and cardiovascular disease prevention. 3rd ed. Winnipeg (MB): Canadian Association of Cardiac Rehabilitation; 2009.
11. Warburton DE, Charlesworth S, Ivey A, et al. A systematic review of the evidence for Canada's physical activity guidelines for adults. Int J Behav Nutr Phys Act 2010;7:39.
12. Gartlehner G. Evidence-based medicine breaking the borders -a working model for the European Union to facilitate evidencebased health care. Wien Med Wochenschr 2004;154:127-32. (Pubitemid 38446407)
13. Schünemann HJ, Woodhead M, Anzueto A, et al. A vision statement on guideline development for respiratory disease: the example of COPD. Lancet 2009;373:774-9.
14. Michie S, Johnston M. Changing clinical behaviour by making guidelines specific. BMJ 2004;328:343-5. (Pubitemid 38197860)
15. Lindsay P, Bayley M, McDonald A, et al. Toward a more effective approach to stroke: Canadian best practice recommendations for stroke care. CMAJ 2008;178:1418-25. (Pubitemid 351775717)
16. van Dis I, Kromhout D, Geleijnse JM, et al. Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil 2010; 17:244-9.
17. New Zealand Guidelines Group. Evidence-based best practice guideline. The assessment and management of cardiovascular risk. Wellington (NZ): The Group; 2003. Available: www.nzgg .org .nz/resources/33/CVC-Risk-Full.pdf (accessed 2011 Aug. 11).
18. Crooke M. New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003. Clin Biochem Rev 2007; 28: 19-29.
19. World Health Organization. Prevention of cardiovascular disease: pocket guidelines for assessment and management of cardiovascular risk. Geneva: The Organization; 2007. Available: www.who.int/cardiovascular-diseases/guidelines/ PocketGL.EN GLISH.AFR-D-E.rev1.pdf (accessed 2011 Aug. 30).
20. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32.
21. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338:1516-20. (Pubitemid 28226280)
22. Burge FI, Bower K, Putnam W, et al. Quality indicators for cardiovascular primary care. Can J Cardiol 2007;23:383-8. (Pubitemid 46901896)
23. Lewanczuk R. Innovations in primary care: implication for hypertension detection and treatment. Can J Cardiol 2006; 22: 614-6. (Pubitemid 44044218)
24. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839-42.
25. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12:18-23.
26. Ward V, House A, Hamer S. Developing a framework for transferring knowledge into action: a thematic analysis of the literature. J Health Serv Res Policy 2009;14:156-64.
27. Tobe SW, Touyz RM, Campbell NR. The Canadian Hypertension Education Program - a unique Canadian knowledge translation program. Can J Cardiol 2007;23:551-5. (Pubitemid 46971158)
28. Eating well with Canada's food guide. Ottawa (ON): Health Canada; 2007. Available: www.hc-sc.gc.ca/fn-an/alt -formats /hpfb -dgpsa/pdf/food-guide- aliment/view-eatwell -vue -bien mang - eng. pdf (accessed 2011 Aug. 11).
29. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50-103.
30. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53. (Pubitemid 351640675)
31. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. (Pubitemid 36712275)
32. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297: 611-9.
33. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006;355:2615-7. (Pubitemid 44969120)
34. Tunstall-Pedoe H. Cardiovascular risk and risk scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart 2011; 97: 442-4.
35. Stone JA. Framing cardiovascular disease event risk prediction. Can J Cardiol 2011;27:171-3.
36. Erbel R, Mohlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010;56:1397-406.
37. Sharman JE, Prins JB. Strengthening the case for global risk assessment of patients with high blood pressure. Am J Hypertens 2009; 22:9.
38. Poulter N. Global risk of cardiovascular disease. Heart. 2003; 89(Suppl 2):ii2-5; discussion ii35-7.
39. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-51.
40. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 2004;23:207-18. (Pubitemid 38365280)
41. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract 2003;53:684-9. (Pubitemid 37107585)
42. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19:596-604. (Pubitemid 35460642)
43. Putnam W, Twohig PL, Burge FI, et al. Evidence-based cardiovascular care. Family physicians' views of obstacles and opportunities. Can Fam Physician 2004;50:1397-405. (Pubitemid 39409551)
44. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv, 1-72.
45. Shiffman RN, Dixon J, Brandt C, et al. The GuideLine Implementability Appraisal (GLIA): development of an instrument to identify obstacles to guideline implementation. BMC Med Inform Decis Mak 2005;5:23.
46. Kastner M, Estey E, Bhattacharyya O. Better guidelines for better care: enhancing the implementability of clinical practice guidelines. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 315-24.
47. Jaspers MW, Smeulers M, Vermeulen H, et al. Effects of clinical decision-support systems on practitioner performance and patient outcomes: a synthesis of high-quality systematic review findings. J Am Med Inform Assoc 2011;18:327-34.
48. Hemmelgarn BR, Chen G, Walker R, et al. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol 2008;24:507-12.